Clinical trial • Phase II • Cardiology
LEVOSIMENDAN for Cardiogenic shock
Phase II trial of LEVOSIMENDAN for Cardiogenic shock.
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Cardiogenic shock
- Trial Stage
- Phase II
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 02-11-2023
- First CTIS Authorization Date
- 11-03-2024
Trial design
Randomised, placebo: cernevit (pulver zur herstellung einer injektions- oder einer infusionslösung) administered as infusion (placebo comparator).-controlled Phase II trial across 1 site in Austria.
- Randomised
- Yes
- Comparator
- Placebo: Cernevit (pulver zur Herstellung einer Injektions- oder einer Infusionslösung) administered as infusion (placebo comparator).
- Target Sample Size
- 46
- Trial Duration For Participant
- 28
Eligibility
Recruits 46 Vulnerable population selected (isVulnerablePopulationSelected=true); no information provided on consent or assent procedures for vulnerable participants..
- Pregnancy Exclusion
- • Pregnant women
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected=true); no information provided on consent or assent procedures for vulnerable participants.
Inclusion criteria
- {"criterion_text":"- Age ≥ 18 years\n- Undergoing ECMO for cardiogenic shock or refractory cardiac arrest"}
Exclusion criteria
- {"criterion_text":"- Coma with fixed dilatation of pupils that was not induced by drugs or other circumstances indicating likely futility\n- Mechanical cause of cardiogenic shock (e.g., ventricular septal defect or papillary muscle rupture)\n- Onset of shock more than 12 hours before screening\n- Massive pulmonary embolism\n- Severe peripheral arterial disease precluding insertion of ECMO cannula\n- Aortic regurgitation greater than grade II in severity (on a scale of I to IV, with higher grades indicating more severe regurgitation)\n- Age > 90 years\n- Severe concomitant disease associated with a life expectancy of less than 6 months\n- Pregnant women"}
Endpoints
Primary endpoints
- {"endpoint_text":"- \tChange in left ventricular outflow tract velocity time integral measured by Doppler echocardiography from baseline to 72h after initiation ECMO or before cessation of ECMO support, whichever occurs first","definition_or_measurement_approach":"Measured by Doppler echocardiography: change in left ventricular outflow tract velocity time integral from baseline to 72 hours after ECMO initiation or before cessation of ECMO support, whichever occurs first."}
Secondary endpoints
- {"endpoint_text":"- Change in pulse pressure from baseline to 72h after initiation of ECMO or before cessation of ECMO support, whichever occurs first\n- ECMO weaning failure, defined as death during ECMO support, death within 24 h after ECMO removal or need for reimplantation of ECMO within 24 h.\n- All cause mortality at 28 days\n- Urinary output for the first 48 hours post cessation of ECMO support\n- Central venous saturation at 4, 8, 12, 24 and 48 hours post cessation of ECMO support\n- Total days requiring ECMO","definition_or_measurement_approach":"Change in pulse pressure: from baseline to 72h after ECMO initiation or before cessation. ECMO weaning failure: defined as death during ECMO support, death within 24 h after ECMO removal or need for reimplantation within 24 h. All-cause mortality assessed at 28 days. Urinary output measured for first 48 hours post cessation. Central venous saturation measured at specified timepoints (4,8,12,24,48 hours). Total days requiring ECMO recorded as days."}
Recruitment
- Planned Sample Size
- 46
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 46
Austria
- Earliest CTIS Part Ii Submission Date
- 29-02-2024
- Latest Decision Or Authorization Date
- 11-03-2024
- Processing Time Days
- 11
- Number Of Sites
- 1
- Number Of Participants
- 46
Sites
- Site Name
- Medical University Of Vienna
- Department Name
- Department of Internal Medicine II, Division of Cardiology
- Principal Investigator Name
- Robert Zilberszac
- Principal Investigator Email
- robert.zilberszac@meduniwien.ac.at
- Contact Person Name
- Robert Zilberszac
- Contact Person Email
- robert.zilberszac@meduniwien.ac.at
Sponsor
Primary sponsor
- Full Name
- Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Austria
Co-sponsors
- Medical University Of Vienna
Investigational products
- Investigational Product Name
- Levosimendan EQL Pharma 2,5mg/ml Konzentrat zur Herstellung einer Infusionslösung
- Active Substance
- LEVOSIMENDAN
- Modality
- Small molecule
- Routes Of Administration
- Infusion
- Route
- Infusion
- Authorisation Status
- Authorised in AT (marketing authorisation number 141525)
- Maximum Dose
- 12.5 mg
- Investigational Product Name
- Cernevit, Pulver zur Herstellung einer Injektions- oder einer Infusionslösung
- Active Substance
- Retinol palmitate; Ascorbic acid; Colecalciferol; Cyanocobalamin; Dexpanthenol; Folic acid; Nicotinamide; Pyridoxine hydrochloride; Riboflavin sodium phosphate dihydrate; D-biotin; DL-alpha-tocopherol; Cocarboxylase tetrahydrate
- Modality
- Small molecule
- Routes Of Administration
- Infusion
- Route
- Infusion
- Authorisation Status
- Authorised in BE (marketing authorisation number BE152223)
- Maximum Dose
- 1 U unit(s)
Related trials
Other published trials that may interest you.